Clinical characteristics and risk factors of chronic hepatitis C complicated by fatty liver
10.3760/cma.j.cn341190-20220329-00263
- VernacularTitle:慢性丙型肝炎合并脂肪肝的临床特征及危险因素分析
- Author:
Qinxiang KONG
1
;
Jinling DONG
Author Information
1. 湖州市第一人民医院感染科，湖州 313000
- Keywords:
Hepatitis C, chronic;
Fatty liver;
Liver function tests;
Prothrombin time;
Blood glucose;
Body mass index;
Risk factors
- From:
Chinese Journal of Primary Medicine and Pharmacy
2022;29(10):1495-1500
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics and risk factors of chronic hepatitis C (CHC) complicated by fatty liver.Methods:The clinical data of 258 patients with chronic hepatitis C who received treatment in The First People's Hospital of Huzhou from March 2017 to March 2021 were included in this study. They were divided into simple CHC group and CHC complicated by fatty liver group according to whether they had fatty liver. General data, liver function, coagulation function and blood lipid indexes were compared between the two groups.Results:Among 258 patients with CHC infection, 81 cases had fatty liver, accounting for 31.40%; 177 cases did not have fatty liver, accounting for 69.14%. There were no significant differences in age, sex, and history of smoking and alcohol use between the two groups (both P > 0.05). Body mass index (BMI) differed significantly between the two groups ( χ2 = 29.81, P < 0.001). BMI in the CHC complicated by fatty liver group was slightly higher than that in the simple CHC group. There were no significant differences in history of hypertension and coronary heart disease between the two groups (both P > 0.05). There were significant differences in the presence of hypertriglyceridemia and the increase of low-density lipoprotein between the two groups ( χ2 = 8.53, 6.99, P = 0.004, 0.008). There were no significant differences in the presence of hypercholesterolemia and the reduction of high-density lipoprotein (both P > 0.05). There were no significant differences in liver function indexes such as alanine aminotransferase and aspartate aminotransferase between the two groups (both P > 0.05). The level of γ-glutamyltransferase (γ-GGT) was significantly different between the two groups ( t =-8.71, P < 0.001). There was no significant difference in activated partial thromboplastin time between the two groups ( P > 0.05). There were significant differences in prothrombin time (PT) and international normalized ratio (INR) between the two groups [PT: (10.10 ± 0.67) seconds vs. (11.99 ± 1.33) seconds; INR: 0.91 ± 0.07 vs. 0.98 ± 0.11; t = 9.74, 4.46, both P < 0.001]. There were no significant differences in fasting blood glucose and blood uric acid levels between the two groups (both P > 0.05). Fasting insulin (FINS) differed significantly between CHC complicated by fatty liver and simple CHC groups [(16.82 ± 1.15) mlU/L vs. (12.52 ± 1.06) mlU/L, t = -24.33, P < 0.001]. The general data and clinical data were compared between the two groups. BMI, hypertriglyceridemia, high- and low-density lipoprotein, γ-GGT, PT, INR and FINS differed significantly between the two groups. Multivariate logistic regression results showed that BMI ≥ 24 kg/m 2, hypertriglyceridemia, γ-GGT, PT, INR and FINS were independent risk factors for CHC complicated by fatty liver ( P = 0.017, 0.003, 0.021, 0.034, 0.004, 0.001). After 6 months of treatment, CHC RNA negative conversion rate in the simple CHC group was significantly higher than that in the CHC complicated by fatty liver group ( χ2 = 7.32, P = 0.010). Conclusion:The related risk factors of CHC complicated by fatty liver include BMI, hypertriglyceridemia, elevated low-density lipoprotein, γ-GGT, PT, INR and FINS, among which, BMI, hypertriglyceridemia, γ-GGT, PT, INR and FINS are independent risk factors. In addition, CHC complicated by fatty liver may affect the efficacy of antiviral therapy.
